The Monash IVF Group Ltd (ASX: MVF) share price is in focus as the company posts FY26 revenue of $269.5 million and declares a final fully franked dividend, despite a 41% fall in underlying net profit after tax (NPAT).

What did Monash IVF Group report?

• Revenue of $269.5 million, down 0.9% from FY25
• Underlying EBITDA of $53.4 million, down 19.5%
• Underlying NPAT of $16.1 million, down 41.2%
• Reported EBITDA of $43.5 million; reported NPAT of $8.3 million
• Final fully franked FY26 dividend of 1.3 cents per share, total FY26 dividends of 2.5 cents (payout ratio 60%)
• Net operating cash flow of $36.7 million (up from $12.9 million in FY25)

What else do investors need to know?

Monash IVF faced a challenging start to FY26, with domestic stimulated cycle volumes softening in the first half. However, momentum improved in the second half, and market share climbed to 20.2%. The company’s international and genetics divisions delivered record results, with offshore revenue rising 15%, and strong growth in specialist genetics testing.

The group focused on strengthening its medical workforce, refreshing leadership, and investing in major infrastructure. Capital expenditure for the year reached $23.8 million, supporting projects like the new Brisbane fertility clinic and increased surgical capacity in Victoria.

What did Monash IVF Group management say?

Speaking about the results, Monash IVF’s CEO, Dr Victoria Atkinson, said:

FY26 was a year of two halves for Monash IVF. While the first half was challenging, we exited the year with improving momentum, with domestic stimulated cycle volume trends strengthening, market share increasing through the second half and our international businesses delivering record performance.

We have used FY26 to strengthen the foundations of the business—building our medical workforce, strengthening leadership and governance, completing significant infrastructure investment and commencing a structural productivity program. We have also launched Nurture 2030, our three-year strategy to accelerate sustainable growth and create stronger returns.

We enter FY27 with multiple growth engines strengthened and a clear focus on execution: growing domestic stimulated cycle volumes, expanding market share, unlocking our completed capital investments, improving productivity and continuing to scale International, Genetics and Diagnostics. With the foundations now in place, Monash IVF is positioned to convert volume growth into stronger earnings through operating leverage and strategic execution.

What’s next for Monash IVF Group?

Looking to FY27, Monash IVF expects stronger financial performance as market conditions improve and expansion efforts take hold. Key priorities include connecting patient journeys with better data, expanding clinical specialties, and embedding ongoing productivity gains.

The group aims to reduce capital expenditure by 50% and reignite organic growth in key states like Victoria and NSW. Management also notes Monash IVF’s strong governance will help it efficiently implement new industry regulations, supporting future returns.

Monash IVF Group share price snapshot

The Monash IVF share price has underperformed the S&P/ASX 200 index (ASX: XJO) over the past 12 months with a decline of around 4%.

View Original Announcement

The post Monash IVF Group earnings: FY26 profit slips, outlook improves appeared first on The Motley Fool Australia.

More reading

• Strike Energy posts project breakthrough, secures West Erregulla funding
• Bell Potter says this ASX healthcare share could rise 200%+
• Wildcat Resources delivers more high-grade lithium drill results
• 3 ASX dividend shares raising dividends like clockwork
• Liontown FY26 results: Maiden profit, record revenue as lithium prices rebound

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Strike Energy Ltd (ASX: STX) share price is in focus today after the company announced a breakthrough securing a gas processing pathway and funding for its West Erregulla development, alongside updates on its key projects and strengthened financial position.

What did Strike Energy report?

• Selected Hancock Energy’s proposed Belisama facility as preferred gas processing pathway for West Erregulla
• Secured up to $30 million in funding support from Hancock Energy for pre-development activities
• Amended Macquarie Bank facility to increase available funding to $30 million, with no amortisation until maturity in 2029
• South Erregulla Power Project commissioning now targeting approval to generate in late Q4 CY26
• Walyering gas field 2P sales gas reserves increased to 16.4 PJ after FY26 production, with production ramp-up underway

What else do investors need to know?

Strike’s new agreements provide a clear and coordinated pathway to develop West Erregulla, targeting a final investment decision in FY28 and first gas by mid-2029. The funding and processing arrangements with Hancock Energy de-risk the project and cement Strike’s shift to a more diversified earnings base.

The company’s South Erregulla Power Project is progressing towards approval to begin generating in the final quarter of 2026. Meanwhile, at Walyering, the successful commissioning of new compressors is expected to boost production capacity towards 20 TJ per day.

Looking ahead, Strike is also accelerating its exploration program in the Perth Basin, including planned seismic surveys in FY27 focused on wholly owned prospects like Ocean Hill and Kadathinni.

What did Strike Energy management say?

Strike Energy’s Managing Director and CEO, Shelley Robertson said:

Today’s announcement marks an important step in unlocking the value of West Erregulla and progressing one of Western Australia’s largest undeveloped onshore gas resources toward production. By selecting Hancock Energy’s Belisama facility and securing a funding framework with Hancock Energy and through an existing facility with Macquarie that supports development activities towards first gas, we have materially reduced both execution and funding risk for the project. Importantly, these arrangements provide Strike with a clear pathway to participate in the development of West Erregulla while maintaining balance sheet flexibility and minimising dilution for shareholders. Together with the cash flows from Walyering and the expected commencement of South Erregulla, West Erregulla forms the third pillar of a diversified energy portfolio that we believe can generate significant long-term value for shareholders. As Western Australia continues to require reliable domestic gas to support economic growth and the energy transition, Strike is increasingly well-positioned to play a meaningful role in delivering secure, affordable energy to the State.

What’s next for Strike Energy?

Strike and Hancock Energy will now work to finalise binding agreements and progress the West Erregulla joint venture to reach a final investment decision around FY28. If all goes to plan, first gas is expected from West Erregulla by mid-2029, which would add further cash flow alongside Walyering and South Erregulla.

The company is also preparing for expansion, with a focus on high-impact exploration opportunities in the Perth Basin to drive future growth and value creation for shareholders over the years ahead.

Strike Energy share price snapshot

Over the past 12 months, Strike Energy shares have declined 13%, trailing the All Ordinaries Index (ASX: XAO), which has risen

View Original Announcement

The post Strike Energy posts project breakthrough, secures West Erregulla funding appeared first on The Motley Fool Australia.

More reading

• Strike Energy upgrades Walyering gas reserves and books maiden Walyering West discovery

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Saluda Medical Inc (ASX: SLD) shares had a day to forget on Friday.

The ASX healthcare share ended the week with a 25% decline to 48 cents after the market responded negatively to its FY 2026 results.

While this is disappointing, the team at Bell Potter believes it could have created a very attractive buying opportunity.

What is the broker saying?

Saluda Medical is a medical device company commercialising spinal cord stimulation (SCS) therapy. 

Bell Potter notes the ASX healthcare share reported higher than expected operating expenses in FY 2026, which resulted in a sizeable adjusted EBITDA loss. It said:

Revenue was pre-released at the Q4 update, increasing +28% for the full year with a particularly strong 2H (up +38% on pcp). Gross margin of 48.9% was ahead of our forecast (48.5%) and improved +2.3% yoy. Opex was above our forecast, resulting in loss at EBITDA (adjusted) of -$113.7m albeit still coming better than Prospectus guidance of -$114.7m.

However, there were positives. It adds:

In SLD’s first full-year result since listing, management has beaten each key metric guided to at the time of the IPO (revenue, EBITDA loss, cashflow). Closing cash balance was $116m and excludes $25m of undrawn debt available under the Perceptive loan available to be drawn down in 1H FY27.

Looking ahead, Bell Potter points out that management is guiding to more strong top line growth and another EBITDA loss. It adds:

The company provided four key FY27 guidance statements: (1) revenue growth of 25-35% ($113m-122m); (2) gross margin 50%-52% while reiterating the longer-term target of ‘mid-60s’ once the next generation IPG and percutaneous leads are submitted to and approved by the FDA (launch guided to CY27); (3) adjusted EBITDA loss $101-95m; and (4) revenue growth to outpace opex growth. 

Big potential returns

Bell Potter remains very positive on the ASX healthcare share.

In response to its results, the broker has retained its buy rating and $1.60 price target on its shares.

Based on its current share price, this implies potential upside of approximately 230% for investors over the next 12 months.

Speaking about its buy thesis, Bell Potter said:

SLD’s US commercial execution continues to impress and accelerated considerably in recent quarters (34% US growth in Q3, 45% in Q4). Tailwinds continue to build following FDA approval of SLD’s paddle lead in June and ~40% of the current sales force expected to complete training in FY27 and contribute to revenue generation. Real-world data continues to affirm Evoke’s value proposition: greater efficacy durability means fewer reprogramming requirements and therefore greater revenue/rep compared to conventional devices.

The post Bell Potter says this ASX healthcare share could rise 200%+ appeared first on The Motley Fool Australia.

More reading

• Monash IVF Group earnings: FY26 profit slips, outlook improves
• Strike Energy posts project breakthrough, secures West Erregulla funding
• Wildcat Resources delivers more high-grade lithium drill results
• 3 ASX dividend shares raising dividends like clockwork
• Liontown FY26 results: Maiden profit, record revenue as lithium prices rebound

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.